Exelixis (EXEL) Receives a Hold from RBC Capital
In a report released on January 29, Leonid Timashev from RBC Capital maintained a Hold rating on Exelixis, with a price target of $45.00. The company’s shares closed yesterday at $42.28.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Timashev covers the Healthcare sector, focusing on stocks such as BeOne Medicines, Exelixis, and Axsome Therapeutics. According to TipRanks, Timashev has an average return of 21.2% and a 56.88% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Exelixis with a $45.80 average price target.
Based on Exelixis’ latest earnings release for the quarter ending October 3, the company reported a quarterly revenue of $597.76 million and a net profit of $193.58 million. In comparison, last year the company earned a revenue of $539.54 million and had a net profit of $117.97 million
Based on the recent corporate insider activity of 86 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EXEL in relation to earlier this year. Most recently, in November 2025, DAVID EDWARD JOHNSON, a Director at EXEL bought 27,532.00 shares for a total of $1,187,179.84.
Read More on EXEL:
Disclaimer & DisclosureReport an Issue
- Exelixis price target raised to $52 from $49 at H.C. Wainwright
- Exelixis price target raised to $51 from $49 at Truist
- Exelixis reports preliminary FY25 revenue $2.32B, consensus $2.33B
- Exelixis sees FY26 revenue $2.525B-$2.625B, consensus $2.62B
- Exelixis downgraded to Equal Weight from Overweight at Morgan Stanley
